Table 3.
Results of multivariate analyses for overall survival, leukemia-free survival, relapse and treatment-related mortality among recipients of HLA-identical sibling donor transplantation
| Variable | Hazard ratio* | 95% confidence intervals |
P-value |
|---|---|---|---|
| Overall survival† | |||
| Age at transplant, years | |||
| Children | 1.0 | - | <0.01‡ |
| Adolescent and young adults | 1.22 | 1.03-1.44 | 0.02 |
| Older adults | 1.68 | 1.41-2.00 | <0.01 |
| Year of transplant | |||
| 1980-1988 | 1.0 | - | <0.01§ |
| 1989-1997 | 0.83 | 0.73-0.95 | <0.01 |
| 1998-2005 (> 3 months after HCT) | 0.55 | 0.44-0.70 | <0.01 |
| 1998-2005 (≥ 3 months after HCT) | 0.88 | 0.74-1.05 | 0.15 |
| Leukemia-free survival∥ | |||
| Age at transplant, years | |||
| Children | 1.0 | - | <0.01‡ |
| Adolescent and young adults | 1.14 | 0.97-1.34 | 0.11 |
| Older adults | 1.47 | 1.24-1.75 | <0.01 |
| Year of transplant | |||
| 1980-1988 | 1.0 | - | 0.06‡ |
| 1989-1997 | 0.87 | 0.77-1.00 | 0.05 |
| 1998-2005 | 0.83 | 0.70-0.99 | 0.02 |
| Relapse¶ | |||
| Age at transplant, years | |||
| Children | 1.0 | - | 0.02‡ |
| Adolescent and young adults | 0.76 | 0.62-0.93 | <0.01 |
| Older adults | 0.77 | 0.62-0.96 | 0.02 |
| Year of transplant | |||
| 1980-1988 | 1.0 | - | <0.01§ |
| 1989-1997 | 1.10 | 0.90-1.34 | 0.35 |
| 1998-2005 (> 3 months after HCT) | 1.66 | 1.24-2.22 | <0.01 |
| 1998-2005 (≥ 3 months after HCT) | 1.18 | 0.92-1.52 | 0.20 |
| Treatment-related mortality** | |||
| Age at transplant, years | |||
| Children | 1.0 | - | <0.01‡ |
| Adolescent and young adults | 2.06 | 1.55-2.73 | <0.01 |
| Older adults | 3.40 | 2.53-4.56 | <0.01 |
| Year of transplant | |||
| 1980-1988 | 1.0 | - | <0.01§ |
| 1989-1997 | 0.65 | 0.55-0.77 | <0.01 |
| 1998-2005 (> 6 months after HCT) | 0.38 | 0.30-0.48 | <0.01 |
| 1998-2005 (≥ 6 months after HCT) | 0.64 | 0.47-0.85 | <0.01 |
Hazard ratios refer to hazards of death or relapse
Other variables significantly associated with overall survival included cytogenetic risk at diagnosis, disease status at transplant, time from diagnosis to transplant, performance status score at transplant and patient gender (also see Appendix Table 3)
Overall P-value, 2 degrees of freedom test
Overall P-value, 3 degrees of freedom test
Other variables significantly associated with leukemia-free survival included gender, cytogenetic risk at diagnosis, disease status at transplant, time from diagnosis to transplant and performance status score at transplant (also see Appendix Table 3)
Other variables significantly associated with relapse included cytogenetic risk at diagnosis, disease status at transplant, time from diagnosis to transplant and performance status score at transplant (also see Appendix Table 3)
Other variables significantly associated with treatment-related mortality included disease status at transplant, time from diagnosis to transplant and performance status score at transplant (also see Appendix Table 3)